Studying the effect of enzyme Injections to reduce muscle tightness in people with brain or spinal cord-related movement disorders

EVALUATING THE EFFICACY OF INTRAMUSCULAR HYALURONIDASE INJECTIONS FOR FOCAL MUSCLE SPASTICITY IN UPPER MOTOR NEURON DISEASES - AN INTERVENTIONAL STUDY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113526

Enrollment

Registered

2026-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S140- Concussion and edema of cervical spinal cord Health Condition 2: S240- Concussion and edema of thoracic spinal cord Health Condition 3: S063- Focal traumatic brain injury Health Condition 4: S341- Other and unspecified injury of lumbar and sacral spinal cord Health Condition 5: G822- Paraplegia Health Condition 6: G825- Quadriplegia Health Condition 7: G811- Spastic hemiplegia

Interventions

Intervention1: intramuscular hyaluronidase injections for focal muscle spasticity in upper motor neuron diseases: Detailed history including sociodemographic details, detailed clinical examination. (e

Eligibility

Inclusion criteria

Inclusion criteria: Upper motor neuron lesion cases admitted in our institute with more than 3 months from the onset of illness like SCI,STROKE,TBI. Spastic muscle group with Modified Ashworth Score grade of more than or equal to 3 not reduced by conventional oral antispasticity drugs. Compliant with exercise therapy program for 1 month follow up period.

Exclusion criteria

Exclusion criteria: Coronary artery Disease, Chronic Kidney disease, Liver disorder, Non adherence to protocol,Severe Cognitive deficit

Design outcomes

Primary

Measure	Time frame
MAS - Modified Ashworth scale. Timepoint: at baseline, Immediately after procedure, 1 week and 4 week	—

Secondary

Measure	Time frame
PRoM Passive Range of Motion VAS Visual Analogue Scale Timepoint: evaluated before, 10 minutes after procedure, at 1 week and at 1 month from the day of injection	—

Countries

India

Contacts

Public ContactABINAYA AARTHI K

Madras Medical College

arasupmr@gmail.com9444367919

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026